Candel Therapeutics' phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer shows positive interim survival data.
Candel Therapeutics shares soar 34% after positive interim survival data from its phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer. Updated data showed prolonged and sustained survival for patients with borderline resectable pancreatic ductal adenocarcinoma, with an estimated median overall survival of 28.8 months. The FDA granted Fast Track Designation to CAN-2409 in combination with valacyclovir.
April 04, 2024
3 Articles